Neurobo pharmaceuticals, inc. (GEMP)
Income statement / TTM
Mar'20Dec'19Sep'19Jun'19Mar'19Dec'18Sep'18Jun'18Mar'18Dec'17Sep'17Jun'17Mar'17Dec'16Sep'16Jun'16Mar'16Dec'15Sep'15Jun'15Mar'15
Operating expenses:
Research and development

5,676

5,324

5,935

8,409

11,135

14,312

17,559

20,506

22,383

22,686

22,445

17,892

12,844

8,740

5,365

4,798

4,961

3,991

0

0

0

Acquired in‑process research and development

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

General and administrative

4,647

2,701

4,484

5,598

7,057

8,493

8,512

8,198

10,302

10,438

11,340

10,756

7,129

5,956

4,614

4,145

3,752

3,177

0

0

0

Total operating expenses

22,474

20,176

10,419

14,007

18,192

22,805

26,071

28,704

32,685

33,124

33,785

28,648

19,973

14,696

9,979

8,943

8,713

8,076

0

0

0

Loss from operations

-22,474

-20,176

-10,419

-14,007

-18,192

-22,805

-26,071

-28,704

-32,685

-33,124

-33,785

-28,648

-19,973

-14,696

-9,979

-8,943

-8,713

-8,076

0

0

0

Interest (expense) income, net

11

-22

-177

-353

-507

-654

-655

-615

-458

-286

-94

-437

-1

114

238

504

55

-762

0

0

0

Loss on note extinguishment

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

-

-

-

Other income (expense), net

0

-

-2,045

-930

-

0

0

-

-

-5

-4

-5

-5

-4

-3

4

3

0

0

0

-

Loss before income taxes

-23,578

-21,312

-12,470

-15,119

-18,877

-23,637

-26,727

-29,319

-33,143

-33,415

-33,883

-29,090

-19,979

-14,586

-9,942

-8,633

-8,853

-9,029

0

0

0

Provision for income taxes

0

0

0

0

0

-

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

Net loss

-23,578

-21,312

-12,470

-15,119

-18,877

-23,637

-26,727

-29,319

-33,143

-33,415

-33,883

-29,090

-19,979

-14,586

-9,942

-8,633

-8,853

-9,029

0

0

0

Other comprehensive loss:
Foreign currency translation loss, net of tax

0

-

-

-

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Total other comprehensive loss

-22

10

0

0

0

2

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

Comprehensive loss

-23,600

-21,302

-12,472

-15,121

-18,879

-23,637

-26,727

-29,319

-33,143

-33,415

-33,883

-29,090

-19,979

-14,586

-9,942

-8,633

-8,853

-9,029

0

0

0

Net loss

-23,578

-21,312

-12,470

-15,119

-18,877

-23,637

-26,727

-29,319

-33,143

-33,415

-33,883

-29,090

-19,979

-14,586

-9,942

-8,633

-8,853

-9,029

0

0

0

Adjustment to redemption value on Series A convertible preferred stock

-

-

-

-

-

-

-

-

-

0

0

67

217

366

516

601

600

2,968

0

0

0

Premium upon substantial modification of convertible note with certain shareholders

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

-

-

-

Net loss attributable to common stockholders

-

-

-

-

-

-

-

-

-

-

-

-

-

-14,952

-11,505

-10,281

-10,500

-13,044

0

0

0

Loss per share:
Net loss per share, basic and diluted (Note 11)

-0.30

-3.16

-0.24

-0.20

-0.48

-0.26

-0.43

-0.47

-0.58

-

-

-

-

0.78

0.56

0.42

0.65

-1.14

-0.87

-0.60

-2.27

Weighted average common shares outstanding:
Basic and diluted

15,670

-12,800

14,265

14,265

5,166

-23,926

14,259

14,232

12,439

-

-

-

-

-

-

-

-

-

-

-

-